DPLIFE PRIME
DPLIFE-PRIME
Composition:
Each Enteric-coated Tablet contains: |
Doxylamine succinate 20 mg |
Pyridoxal 5’-Phosphate 10 mg |
L-Methylfolate calcium 1 mg |
Mecobalamin IP 1500 mcg |
Pharmacodynamic
Doxylamine succinate:
Doxylamine succinate is classified as an antihistamine
Doxylamine Succinate effectively blocks the Chemo Receptor Trigger Zone thereby inhibiting the binding of neurotransmitters and controls Nausea
Pyridoxal 5’-Phosphate
Bioactive form of Pyridoxine Hydrochloride (Vitamin B6). Has been known to possess antiemetic effects though the mechanism of action is not well know. Well tested for efficacy and safety in NVP, alone and in combination with Doxylamine succinate
L-MethylFolate (LMF)
Bioactive form of Folic acid
Significantly lowers risk of NTDs & Cleft palate
Significantly lowers the risk of Hyperhomocysteinemia and the associated risks & complications in Pregnancy
MECOBALAMIN
Bioactive form of Vitamin B12
Reduces risks of Neural Tube defects alongwith Folate
Lowers the risk of Hyperhomocysteinemia and associated Pregnancy Complications
Indication:
For the Prevention & Treatment of Nausea & Vomiting of Pregnancy
To reduce the Risk of Neural Tube Defects
To reduce the risk of Hyperhomocysteinemia & its complications in pregnancy
Dosage:
1 Tablet Daily or as Directed by the Physician
Storage:
Store protected from light & moisture, at a temperature not exceeding 25°C
Pharmacokinetic:
Absorbed mainly from the jejunum (small intestine). Hence enteric-coated tablets used. Peak plasma concentrations, after using delayed-release preparations is around 4-7 hours (Hence the drug is given at bedtime). Doxylamine is metabolised in the liver. Metabolites are excreted through kidneys